GW Pharma

Curated by Signal

Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy

Overview

Developer of cannabinoid medicines for MS spasticity, cancer pain, and childhood epilepsy. The drugs include Sativex for the treatment of MS spasticity and cancer pain and Epidiolex for the treatment of childhood epilepsy. Sativex is indicated as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis.

Key facts

Founded: 1998
Headquarters: Cambridge, United Kingdom
Stage: Sign up to view
Industry: Health Technology

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

Florence
Online platform for on-demand recruitment of healthcare professionals
Health TechnologyLondon, United Kingdom
Motivational Life
App based platfrom for meditation
Health TechnologyLondon, United Kingdom
dbRotas
Provider of custom doctor rostering solution for healthcare organisation
Health TechnologyEastleigh, United Kingdom

About GW Pharma

What does GW Pharma do?

Developer of cannabinoid medicines for MS spasticity, cancer pain, and childhood epilepsy.

Where is GW Pharma headquartered?

GW Pharma is headquartered in Cambridge, United Kingdom.

When was GW Pharma founded?

GW Pharma was founded in 1998.

Which sector is GW Pharma in?

GW Pharma operates in Health Technology.

Who are GW Pharma's competitors?

Companies similar to GW Pharma include Florence, Motivational Life, and dbRotas.